Using the Antigenic Signature of Self-renewing GBM Cells to Target Low & High Mutational Tumor Burden
Time: 9:45 am
day: Conference Day 2
Details:
- Autologous dendritic cells loaded with autologous tumor antigens from self-renewing tumor initiating cells as personal therapeutic cancer vaccines
- Lessons learned from a single-arm phase 2 trial in primary GBM
- Randomized, blinded phase 3 trial in primary GBM
